# RECORDATI GROUP clinical trials: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials with RECORDATI GROUP as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by RECORDATI GROUP: 27 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/recordati-group

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 31, 2025 | NCT07312643 | Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose... | RECORDATI GROUP | Phase 1 | Completed | Pharmacokinetics, Safety | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312643) |
| November 25, 2025 | NCT07247162 | Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome | RECORDATI GROUP | Phase 4 | Recruiting | Hypertension, Hypercortisolemia, Cushing Syndrome | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247162) |
| August 16, 2023 | NCT05995834 | Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS) | RECORDATI GROUP | Observational | Unknown | Idiopathic Multicentric Castleman's Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05995834) |
| July 3, 2023 | NCT05928390 | Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia | RECORDATI GROUP | Phase 2 | Active not recruiting | Post-Bariatric Hypoglycemia | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05928390) |
| March 30, 2023 | NCT05791708 | Cold Agglutinin Disease Real World Evidence Registry | RECORDATI GROUP | Observational | Active not recruiting | Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS) | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05791708) |
| December 1, 2022 | NCT05633953 | Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome | RECORDATI GROUP | Observational | Completed | Cushing's Syndrome | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633953) |
| May 19, 2022 | NCT05382156 | Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome | RECORDATI GROUP | Observational | Active not recruiting | Endogenous Cushing's Syndrome | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05382156) |
| March 3, 2022 | NCT05265442 | Real-life Observational Study of Cancer Pain Management With Methadone | RECORDATI GROUP | Observational | Completed | Cancer Pain | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05265442) |
| September 10, 2021 | NCT05040178 | An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics | RECORDATI GROUP | Observational | Recruiting | Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05040178) |
| April 9, 2021 | NCT04838860 | Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease | RECORDATI GROUP | Phase 2 | Terminated | Idiopathic Multicentric Castleman's Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04838860) |
| November 5, 2020 | NCT04616586 | SILtuximab in Viral ARds (SILVAR) Study | RECORDATI GROUP | Phase 3 | Terminated | Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04616586) |
| February 19, 2020 | NCT04276558 | REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients | RECORDATI GROUP | Phase 2 | Completed | Neurotrophic Keratitis | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04276558) |
| February 5, 2020 | NCT04253015 | A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta | RECORDATI GROUP | Observational | Active not recruiting | Neuroblastoma | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04253015) |
| November 25, 2019 | NCT04176523 | Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach | RECORDATI GROUP | Observational | Recruiting | Methylmalonic Acidemia, Propionic Acidemia | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04176523) |
| October 14, 2019 | NCT04125927 | Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) | RECORDATI GROUP | Phase 3 | Completed | Cystinosis | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04125927) |
| June 18, 2019 | NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer | RECORDATI GROUP | Observational | Withdrawn | Prostate Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03990194) |
| October 17, 2018 | NCT03708900 | Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | RECORDATI GROUP | Phase 2 | Recruiting | Cushing Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03708900) |
| July 30, 2018 | NCT03606408 | Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 | RECORDATI GROUP | Phase 2 | Completed | Cushing's Syndrome | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03606408) |
| March 29, 2018 | NCT03482037 | Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury | RECORDATI GROUP | Phase 1/2 | Completed | Neurogenic Detrusor Overactivity | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03482037) |
| June 7, 2017 | NCT03179670 | Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH | RECORDATI GROUP | Observational | Completed | Benign Prostatic Hyperplasia | 625 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03179670) |
| December 8, 2014 | NCT02310269 | Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease | RECORDATI GROUP | Observational | Completed | Cushings Disease | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02310269) |
| December 6, 2013 | NCT02003742 | Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH | RECORDATI GROUP | Phase 3 | Terminated | Lower Urinary Tract Symptoms | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02003742) |
| February 20, 2013 | NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | RECORDATI GROUP | Phase 4 | Completed | Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping... | 337 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01794793) |
| February 15, 2013 | NCT01793480 | Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain... | RECORDATI GROUP | Phase 3 | Completed | Pain Related to Cancer | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01793480) |
| December 31, 2012 | NCT01757769 | Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia | RECORDATI GROUP | Phase 4 | Completed | Benign Prostatic Hyperplasia | 1,036 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01757769) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 3 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Active not recruiting | 4 |
| Recruiting | 4 |
| Terminated | 3 |
| Withdrawn | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Cushing Syndrome | 5 |
| Prostatic Hyperplasia | 3 |
| Hypertension | 2 |
| Lower Urinary Tract Symptoms | 2 |
| Prostatic Neoplasms | 2 |
| Methylmalonic acidemia | 2 |
| Propionic Acidemia | 2 |
| Pituitary ACTH Hypersecretion | 2 |
| Neoplasms | 2 |
| Multi-centric Castleman's Disease | 2 |
| Anemia, Hemolytic, Autoimmune | 1 |
| ACTH Syndrome, Ectopic | 1 |
| Cystinosis | 1 |
| Cancer Pain | 1 |
| Hyperammonemia | 1 |
| Acromegaly | 1 |
| Neuroendocrine Tumors | 1 |
| Pituitary Neoplasms | 1 |
| Dumping Syndrome | 1 |
| Melanoma | 1 |
| Adrenocortical Hyperfunction | 1 |
| Essential Hypertension | 1 |
| Pituitary Diseases | 1 |
| Respiratory Distress Syndrome | 1 |
| Lung Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
